Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertrophic Cardiomyopathy.

Elijah R. Behr1, William J. McKenna

  • 1Cardiological Sciences, St. George's Hospital Medical School, Cranmer Terrace, Tooting, London SW17 0RE, UK. wmckenna@sghms.ac.uk

Current Treatment Options in Cardiovascular Medicine
|November 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beta adrenergic blockers in chronic congestive cardiac failure: a call for action.

European journal of internal medicine·2002
Same author

Cardiovascular Complications of Neuromuscular Disorders.

Current treatment options in cardiovascular medicine·2002
See all related articles

Hypertrophic cardiomyopathy (HCM) management involves family screening via ECG and echocardiogram, genetic testing for uncertainties, and tailored therapies including beta-blockers, calcium channel blockers, or disopyramide. Risk stratification for sudden cardiac death is crucial.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart condition often inherited in an autosomal-dominant pattern.
  • Early diagnosis and management are essential for affected individuals and their families.

Purpose of the Study:

  • To outline the diagnostic and therapeutic strategies for hypertrophic cardiomyopathy (HCM).
  • To emphasize risk stratification for sudden cardiac death and thromboembolic events.

Main Methods:

  • Family screening with electrocardiogram (ECG) and echocardiogram for potential Mendelian autosomal-dominant inheritance.
  • Consideration of genetic testing for high-risk mutations with diagnostic uncertainties.
  • Pharmacological interventions including beta-blockers, calcium channel blockers, and disopyramide.

Related Experiment Videos

  • Non-pharmacological treatments such as surgical myectomy, alcohol septal ablation, and dual-chamber pacing.
  • Close monitoring for atrial fibrillation (AF) and thromboembolic risk, with a low threshold for anticoagulation.

    • Main Results:

    • Beta-blockers are first-line therapy for symptom relief.
    • Disopyramide is effective for obstructive HCM, ideally with beta-blockers.
    • Surgical myectomy is the gold standard, while septal ablation offers good results in experienced hands.
    • Atrial fibrillation and left atrial enlargement increase thromboembolic risk.
    • Key predictors of sudden cardiac death include prior cardiac arrest, syncope, family history, exercise BP response, VT, and severe LVH.

    Conclusions:

    • Comprehensive evaluation including family screening, genetic testing, and risk stratification is vital for HCM management.
    • Pharmacological and non-pharmacological therapies should be individualized based on disease phenotype and patient risk.
    • Vigilant monitoring for arrhythmias and thromboembolic events, with prompt anticoagulation when indicated, is critical.